AstraZeneca PLC

LSE-AZN

Operating Activities	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24
Net Income	3,244	3,127	3,402	1,666	1,828	2,397
Profit Before Tax
Depreciation & Amortization	1,549	1,389	1,284	2,337	1,817	1,279
Depreciation, Amortisation and Impairment
Other Adjustments	596	602	238	264	860	687
Finance Income and Expense
Share of After Tax Income of Associates and Joint Ventures
Gains on Disposal of Intangible Assets
Gains on Disposal of Investments in Associates and Joint Ventures
Fair Value Movements on Contingent Consideration Arising from Business Combinations
Non-Cash and Other Movements
Changes in Trade Receivables	—	—	—	-1,624	-812	—
Change in Trade and Other Receivables
Changes in Inventories	—	—	—	-131	-65.5	—
Change in Inventories
Changes in Accounts Payable	—	—	—	862	431	—
Change in Trade and Other Payables and Provisions
Changes in Income Taxes Payable	-644	-1,186	-363	-772	-641	-907
Tax Paid
Changes in Other Operating Activities	389	-546	-848	305	-451	-371
Change in Working Capital and Short-Term Provisions
Interest Paid
Cash from Operating Activities	5,134	3,386	3,713	2,907	3,383	3,085
Net Cash Inflow from Operating Activities

Investing Activities	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24
Capital Expenditure	-686	-659	-429	-708	-417	-382
Purchase of Property, Plant and Equipment
Proceeds from Sale of Property, Plant & Equipment	—	9	1	2	1	26.5
Disposal of Property, Plant and Equipment
Purchases of Intangible Assets	-1,040	-1,264	-540	-247	-941	-286
Purchase of Intangible Assets
Proceeds from Sale of Intangible Assets	1	86	9	16	32	37.5
Disposal of Intangible Assets
Purchases of Investments	-30	-188	—	-14.5	-29	-26
Purchase of Non-Current Asset Investments
Proceeds from Sale of Investments	7	114	1	-32	47	141
Disposal of Non-Current Asset Investments
Change in Short-Term Investments, Fixed Deposits and Other Investing Instruments
Payments for Business Acquisitions	-328	-267	-362	-274	-264.5	-2,297
Non-Contingent Payments on Business Combinations
Acquisition of Subsidiaries, Net of Cash Acquired
Payments Upon Vesting of Employee Share Awards Attributable to Business Combinations
Payment of Contingent Consideration from Business Combinations
Other Investing Activities	75	61	67	53	57	-22
Change in Profit-Participation Liability
Payments to Associates and Joint Ventures
Disposal of Investments in Associates and Joint Ventures
Interest Received
Payments Made by Subsidiaries to Non-Controlling Interests
Cash from Investing Activities	-2,001	-2,108	-1,253	-1,181	-1,514	-2,872
Net Cash Inflow from Investing Activities

Financing Activities	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24
Issuance of Long-Term Debt	—	9	—	758	1,516	2,488
Issue of Loans and Borrowings
Repayments of Long-Term Debt	-4	-12	-4	-5	-2,004	-2,636
Repayment of Loans and Borrowings
Net Issuance / (Repayments) of Long-Term Debt	-4	-3	-4	753	-488	-148
Issuance of Common Shares	5	4	8	23	4	5
Proceeds from Issue of Share Capital
Repurchases of Common Shares	-19	-3	-486	-40.5	-81	—
Own Shares Purchased by Employee Benefit Trusts
Net Issuance / (Repurchases) of Common Shares	-14	1	-478	-17.5	-77	5
Common Share Dividends Paid	-1,602	42	-3,243	9	-1,552	-21
Dividends Paid
Hedge Contracts Relating to Dividend Payments
Other Financing Activities	-453	530	1,018	-686	-2,014	1,009.5
Payments to Acquire Non-Controlling Interests
Repayment of Obligations Under Leases
Change in Short-Term Borrowings
Payment of Acerta Pharma Share Purchase Liability
Cash from Financing Activities	-2,073	518	-2,707	-671	-4,131	-1,222
Net Cash Inflow from Financing Activities

Free Cash Flow	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24
Free Cash Flow	4,448	2,727	3,284	2,199	2,966	2,703
NOPAT	2,799.9	2,746.3	3,154.5	1,833.1	1,650.9	2,208.7
Levered Free Cash Flow	3,139	1,443	2,561	4,146	1,618.5	1,399
Unlevered Free Cash Flow	3,407.9	1,744.3	2,798.5	3,726.1	2,324.4	1,827.7
Net Change in Cash	1,060	1,796	-247	1,055	-2,262	-1,009